Background
Patients and methods
Study subjects
SNP selection and genotyping
Real-time analyses of LncRNA HOTAIR
Dual luciferase reporter assay
Statistical analysis
Results
Characteristics of study subjects
Category | Stage 1 | Stage 2 | ||||
---|---|---|---|---|---|---|
Cases (N = 400) | Controls (N = 400) | P value | Cases (N = 500) | Controls (N = 500) | P value | |
Age group | ||||||
< 50 | 200 | 192 | 0.572 | 245 | 239 | 0.704 |
≥ 50 | 200 | 208 | 255 | 261 | ||
Gender | ||||||
Male | 240 | 245 | 0.717 | 304 | 299 | 0.747 |
Female | 160 | 155 | 196 | 201 | ||
Drinking | ||||||
Never | 271 | 279 | 0.542 | 333 | 350 | 0.248 |
Ever | 129 | 121 | 167 | 150 | ||
Smoking | ||||||
Never | 291 | 300 | 0.469 | 351 | 369 | 0.205 |
Ever | 109 | 100 | 149 | 131 | ||
Diabetes | ||||||
Yes | 102 | 50 |
< 0.001
| 137 | 66 | < 0.001 |
No | 298 | 350 | 363 | 434 |
Association of SNPs with PC susceptibility
Genotype | Cases | Controls | Crude OR (95% CI) | Adjusted OR (95% CI)a |
---|---|---|---|---|
rs4759314 | ||||
AA | 327 | 354 | 1.00 (reference) | 1.00 (reference) |
AG | 65 | 44 | 1.60 (1.06–2.41) | 1.66 (1.09–2.54) |
GG | 8 | 2 | 4.33 (1.04–18.1) | 4.50 (1.11–18.3) |
G vs A | 1.76 (1.22–2.55) | 1.84 (1.26–2.67) | ||
P trend |
0.024
|
0.018
| ||
rs12427129 | ||||
GG | 359 | 356 | 1.00 (reference) | 1.00 (reference) |
AG | 36 | 41 | 0.87 (0.54–1.39) | 0.91 (0.66–1.25) |
AA | 5 | 3 | 1.65 (0.4–6.87) | 1.72 (0.4–7.43) |
A vs G | 0.98 (0.64–1.49) | 1.02 (0.76–1.35) | ||
P trend | 0.564 | 0.546 | ||
rs200349340 | ||||
GG | 205 | 236 | 1.00 (reference) | 1.00 (reference) |
TG | 161 | 140 | 1.32 (0.99–1.78) | 1.38 (1.00–1.89) |
TT | 34 | 24 | 1.63 (0.94–2.83) | 1.70 (0.96–2.99) |
T vs G | 1.31 (1.04–1.63) | 1.36 (1.06–1.73) | ||
P trend | 0.061 |
0.014
| ||
rs12312094 | ||||
CC | 260 | 278 | 1.00 (reference) | 1.00 (reference) |
CG | 128 | 116 | 1.18 (0.87–1.6) | 1.18 (0.87–1.60) |
GG | 12 | 6 | 2.14 (0.81–5.66) | 2.13 (0.81–5.65) |
G vs C | 1.23 (0.95–1.59) | 1.23 (0.89–1.70) | ||
P trend | 0.284 | 0.214 | ||
rs1838169 | ||||
CC | 269 | 275 | 1.00 (reference) | 1.00 (reference) |
CG | 122 | 118 | 1.06 (0.78–1.43) | 1.10 (0.67–1.80) |
GG | 9 | 7 | 1.31 (0.48–3.57) | 1.37 (0.46–4.06) |
G vs C | 1.07 (0.83–1.39) | 1.12 (0.76–1.64) | ||
P trend | 0.721 | 0.577 | ||
rs7958904 | ||||
GG | 215 | 237 | 1.00 (reference) | 1.00 (reference) |
CG | 156 | 136 | 1.26 (0.94–1.7) | 1.31 (0.94–1.82) |
CC | 29 | 27 | 1.18 (0.68–2.06) | 1.23 (0.64–2.36) |
C vs G | 1.17 (0.94–1.47) | 1.22 (0.93–1.59) | ||
P trend | 0.119 | 0.147 |
Genotype | Cases | Controls | Crude OR (95% CI) | Adjusted OR (95% CI)a |
---|---|---|---|---|
rs4759314 | ||||
Stage 2 | ||||
AA | 406 | 437 | 1.00 (reference) | 1.00 (reference) |
AG | 83 | 59 | 1.51 (1.06–2.17) | 1.57 (1.08–2.29) |
GG | 11 | 4 | 2.96 (0.99–8.89) | 3.08 (1.04–9.13) |
G vs A | 1.63 (1.19–2.24) | 1.7 (1.23–2.36) | ||
P trend |
0.023
|
0.017
| ||
Combined | ||||
AA | 733 | 791 | 1.00 (reference) | 1.00 (reference) |
AG | 148 | 103 | 1.55 (1.18–2.03) | 1.61 (1.22–2.13) |
GG | 19 | 6 | 3.42 (1.43–8.16) | 3.55 (1.51–8.36) |
G vs A | 1.69 (1.33–2.15) | 1.76 (1.37–2.25) | ||
P trend |
0.001
|
0.001
| ||
rs200349340 | ||||
Stage 2 | ||||
GG | 264 | 295 | 1.00 (reference) | 1.00 (reference) |
TG | 196 | 175 | 1.25 (0.96–1.63) | 1.30 (0.97–1.74) |
TT | 40 | 30 | 1.49 (0.9–2.45) | 1.54 (0.92–2.61) |
T vs G | 1.24 (1.01–1.52) | 1.29 (1.03–1.62) | ||
P trend | 0.094 |
0.027
| ||
Combined | ||||
GG | 469 | 531 | 1.00 (reference) | 1.00 (reference) |
TG | 357 | 315 | 1.28 (1.06–1.56) | 1.33 (1.07–1.65) |
TT | 74 | 54 | 1.55 (1.07–2.25) | 1.61 (1.10–2.37) |
T vs G | 1.27 (1.09–1.47) | 1.32 (1.12–1.56) | ||
P trend |
0.013
|
0.001
|